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Breast cancer (BC) is a very heterogeneous dis-
ease. Gene-expression profiling has identified 
four molecular classes of BC: basal-like, luminal-
A, luminal-B and human epidermal growth factor 
2 (HER2)-positive BC [Perou et al. 2000]. These 
four classes are very close to the clinical classifica-
tions based on proliferation markers, histological 
grade, expression of estrogen and progesterone 
receptors (ER and PgR) and overexpression of 
HER2.
In this article, we focus on ER- and HER2-
positive BC subclasses. HER2-positive BC repre-
sents approximately 20–25% of BC [Slamon et al. 
1989]. Half of HER2-positive BC expresses ER 
or PgR. Consequently, the subgroup we discuss 
here represents only about 10% of all BC cases. 
However, this subgroup needs specific systemic 
treatment approaches. Although tumor cells 
express ER, these tumors respond poorly to endo-
crine therapy alone, particularly tamoxifen. These 
have a short disease-free survival (DFS) [Azim 
and Piccart, 2010]. There is growing preclinical 
and clinical evidence indicating a complex molec-
ular bidirectional crosstalk between ER and 
HER2 pathways [Arpino et al. 2008; Massarweh 
and Schiff, 2007]. This crosstalk probably consti-
tutes one of the key mechanisms of drug resist-
ance in this subclass of BC. A better understanding 
of this crosstalk is of considerable clinical interest. 
Delaying or even reversing drug resistance seems 
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possible by targeting pathways implicated in this 
crosstalk.
Estrogen receptor and HER2 pathways: 
bidirectional molecular crosstalk
Genomic and nongenomic action of estrogen 
receptor
ER is mainly a nuclear protein with a genomic 
nuclear activity also known as ‘nuclear initiated 
steroid signaling’. Through this activity, ER func-
tions as a ligand-dependent (estrogen) transcrip-
tion factor of genes implicated in BC cell 
proliferation and survival [Osborne and Schiff, 
2005]. ER also has an inhibitory function on a 
subclass of genes, which are mainly transcrip-
tional repressors or genes with antiproliferative or 
proapoptotic functions [Frasor et al. 2003]. The 
transcriptional activity of ER is regulated by the 
binding to coactivator or corepressor proteins. 
Their nuclear levels can considerably influence 
ER signaling [Arpino et al. 2008].
For basic comprehension of bidirectional cross-
talk between the ER and HER2 pathways, it is 
essential to insist on the fact that signaling from 
different growth factor receptor dependent 
kinases phosphorylates various factors in the ER 
pathway, including ER itself. This potentiates ER 
genomic signaling activity on gene transcription 
[Arpino et  al. 2008]. Thus, in the presence of 
hyperactive growth factor receptor signaling, as 
often occurs in BC (e.g. HER2 overexpression), 
an excessive phosphorylation of ER and its coreg-
ulators may severely weaken the inhibitory effects 
of various endocrine therapies [Arpino et  al. 
2008]. It may increase ER transcriptional activity 
in a ligand-independent mode or even in the pres-
ence of selective ER modulators (SERMs) like 
tamoxifen [Schiff et al. 2003].
ER can also induce rapid stimulatory effects on 
different signal transduction pathways independ-
ent of gene transcription. This is called ‘mem-
brane initiated steroid signaling’, and it can be 
activated by both estrogen and SERMs like 
tamoxifen [Massarweh and Schiff, 2007]. This 
mode of action can directly or indirectly activate 
epidermal growth factor receptor (EGFR), HER2 
and insulin-like growth factor receptor 1 (IGFR1) 
[Lee et al. 2000]. This, in turn, activates the EGFR 
downstream kinase cascades (i.e. RAS/MEK/
mitogen-activated protein kinases (MAPK) 
and PI3K/AKT). These downstream kinases 
phosphorylate and activate ER and its coregula-
tors, increasing genomic activities of ER [Schiff 
et  al. 2004]. The genomic and nongenomic 
actions of ER are complementary and not mutu-
ally exclusive.
Mechanisms of resistance to endocrine therapy
Several mechanisms of resistance to endocrine 
therapy have been described. They include the loss 
or modification of ER expression, epigenetic mech-
anisms regulating ER expression and crosstalk 
between ER and different signaling pathways 
[Garcia-Becerra et al. 2013]. The loss of ER expres-
sion can be explained by epigenetic changes, such 
as aberrant methylation of the ER promoter, limit-
ing its transcription. Epigenetic changes are fre-
quent and reversible events. Thus, the inhibition of 
these mechanisms could be a potential therapeutic 
strategy for the treatment of endocrine-resistant 
BC. Hypoxia, overexpression of EGFR or HER2 
and MAPK hyperactivation have also been pro-
posed to explain the loss of ER expression. Different 
models suggest that overexpression of EGFR and 
HER2 contribute to transcriptional repression of 
ER gene. In recent years, interest was focused on 
modification in ER expression and, particularly, in 
gain-of-function mutations in ESR1, the gene 
encoding ER. These mutations are clustered in 
a hotspot within the ligand-binding domain of 
ER and lead to ligand-independent ER activity 
[Jeselsohn et  al. 2015]. Finally, we insist on the 
crosstalk described between ER and different 
signaling pathways as the main mechanism of 
endocrine therapy resistance.
ER can be phosphorylated and activated by intra-
cellular kinases following activation of EGFR or 
IGFR by their ligands. This can result in ligand-
independent activation of the receptor [Schiff 
et al. 2003]. Another mechanism of resistance is 
activation by the agonist effect of SERMs like 
tamoxifen. Phosphorylation of ER coactivators is 
as important as phosphorylation of ER itself. The 
coactivator amplified in breast cancer 1 (AIB1) 
can be activated by multiple cellular kinases.
Two retrospective studies demonstrated that 
tumors with high levels of both AIB1 and HER 
receptors (HER2 or HER3) are less responsive to 
treatment by tamoxifen. This supports the 
hypothesis that increased signaling from the HER 
family activates downstream kinases, which in 
turn activates ER and AIB1 to increase transcrip-
tional activity even in the presence of tamoxifen 
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[Osborne et  al. 2003; Kirkegaard et  al. 2007]. 
This is called de novo resistance to tamoxifen. 
Furthermore, the nongenomic action of ER can 
be activated by high levels of growth factor recep-
tors and their ligands [Shou et al. 2004]. Various 
studies have shown that enhanced expression of 
EGFR and HER2 with activation of downstream 
signalization by p42/44 MAPK and PI3K/AKT/
mTOR is also clearly implicated in acquired 
resistance to hormonal therapy (tamoxifen, estro-
gen depletion and aromatase inhibitor therapy) 
[Arpino et al. 2008; Knowlden et al. 2003; Brodie 
et al. 2007; Jeng et al. 2000].
PgR-negative tumors are less responsive to endo-
crine therapy than PgR-positive tumors. Some 
authors think that an increased activity in growth 
factor receptor pathways is also responsible for 
the loss of PgR [Cui et al. 2003; Petz et al. 2004; 
Arpino et al. 2005]. They hypothesize that sup-
pressed or reduced PgR levels may derive from 
and indicate hyperactivity in the signaling cascade 
generated by EGFR, HER2 and other kinase acti-
vation. This could explain the endocrine resist-
ance [Arpino et al. 2008].
The current understanding is that growth factor 
receptors play central roles in resistance to various 
endocrine therapies. Different clinical observations 
support these models of endocrine resistance.
A meta-analysis examining the interaction 
between HER2 expression and response to endo-
crine treatment in metastatic disease clearly shows 
that HER2-positive BC is less responsive to any 
type of endocrine treatment [De Laurentiis et al. 
2005]. It is interesting to note that EGFR over-
expression is also associated with a poorer 
response to tamoxifen in patients with metastatic 
BC [Arpino et  al. 2004]. Furthermore, results 
from neoadjuvant settings also support the role of 
HER2 and EGFR in resistance to treatment by 
tamoxifen [Ellis et  al. 2001; Zhu et  al. 2004; 
Dowsett et al. 2007]. These neoadjuvant studies 
tend to show a higher efficacy of aromatase inhib-
itors compared with tamoxifen in HER2-positive 
tumors, but no robust conclusion can be made. 
In addition, both agents are associated only with 
short-lived responses [Azim and Piccart, 2010].
Signaling via HER2/MAPK appears to be a main 
mechanism of resistance to different endocrine 
therapies. It is also attractive to target growth fac-
tor receptor signaling in addition to ER itself to 
optimize the treatment benefits [Massarweh and 
Schiff, 2007]. Indeed, xenograft studies have 
confirmed that HER2 targeting in combination 
with endocrine therapy in HER2-overexpressing 
xenografts restores tamoxifen sensitivity and sig-
nificantly delays resistance to estrogen depriva-
tion or fulvestrant [Shou et al. 2004; Massarweh 
et  al. 2006]. There is also a growing interest in 
adding mTOR inhibitors to endocrine therapy to 
delay endocrine resistance because this treatment 
improved progression-free survival (PFS) com-
pared with endocrine therapy alone in patients 
with advanced BC who had relapsing disease 
on treatment with aromatase inhibitors in the 
BOLERO-2 study [Baselga et al. 2012c; Yardley 
et al. 2013].
Mechanisms of resistance to anti-HER2 
therapies
As for resistance to endocrine therapy, there are 
different mechanisms for resistance to anti-HER2 
therapies [Tortora 2011; Rexer and Arteaga, 
2012]. It can be a mechanism intrinsic to the 
target itself, with masking of the antibody binding 
epitope, truncated forms with kinase activity and 
an extracellular domain which neutralizes the 
HER2 antibody, or even with mutations in the 
tyrosine kinase domain.
Resistance can arise from defects in the apoptosis 
pathway and cell cycle control in tumor cells or in 
host factors that participate in drug action. As an 
example, defects in ADCC immunomodulatory 
function of trastuzumab can contribute to the 
resistance.
Resistance can also mainly involve parallel bypass 
signaling pathways to overcome HER2 inhibition. 
It includes upregulation of ligands and heterodi-
merization with EGFR or HER3. There are also 
interactions with other membrane receptors such 
as IGF1R or MET. Loss of phosphatase and ten-
sin homolog (PTEN) or activating mutations of 
the PIK3CA gene promote persistent PI3K activa-
tion, even in the presence of anti-HER2 therapy.
An inverse relationship has been observed between 
expression of growth factor receptors and ER 
[Massarweh and Schiff, 2007]. ER content is 
inversely correlated with EGFR/HER2 levels in 
ER-positive, HER2-positive tumors [Konecny 
et al. 2003]. Preclinical data support the hypothe-
sis that increased growth factor signaling down-
regulates ER expression [Stoica et  al. 2000a, 
2000b; Tang et al. 1996; Oh et al. 2001]. This can 
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lead to a complete loss of ER expression and con-
sequently represents a potential mechanism of 
resistance to endocrine therapy [Massarweh et al. 
2006]. Recent observations support the hypothe-
sis that some HER2-overexpressing tumors that 
are apparently ER negative may actually revert to 
ER positivity after treatment with anti-HER2 
therapy [Munzone et al. 2006; Xia et al. 2006]. A 
preclinical model published by Giuliano and col-
leagues has reported that ER and Bcl2 expression 
are simultaneously increased in BC xenografts 
treated with anti-HER2 therapies [Giuliano et al. 
2015]. A combination of endocrine and anti-
HER2 therapies given simultaneously might ben-
efit ER+/HER2+ cell lines, including those with 
low ER levels [Wang et  al. 2011]. This bidirec-
tional crosstalk between ER and HER2 pathways 
may also contribute to resistance to anti-HER2 
therapy. Moreover, as mentioned above, resist-
ance to trastuzumab is often thought to be medi-
ated by the loss of PTEN, resulting in the 
activation of the PI3K/AKT/mTOR pathway 
[Nahta and O’Regan, 2010; Jensen et  al. 2012; 
Razis et  al. 2011]. Thus, activation of mTOR 
plays a central role in the crosstalk. Due to the fact 
that many of the known resistance mechanisms 
can bypass the HER2-targeted agents, there is 
intense interest in defining new therapeutic targets 
downstream from HER2.
Resistance to endocrine therapies and anti-
HER2 therapies is a crucial downstream element 
of intracellular signaling. From this point of 
view, in addition to the interest in the PI3K/
AKT/mTOR pathway, the CDK4/6 complexes 
represent a new promising target downstream of 
HER2 at the interface between proliferation 
signaling pathways and the cell cycle machinery 
[Witkiewicz et  al. 2014]. There are also down-
stream of the majority of processes driving 
resistance to HER2-targeted therapies and 
endocrine therapies.
Preclinical models: proof of concept of dual 
targeting estrogen receptor and HER2
In a xenograft model, Sabnis and colleagues 
showed that ERα expression is reduced while 
HER2 expression is increased in letrozole-resistant 
cancer cells [Sabnis et al. 2009]. In these cells, the 
addition of trastuzumab to letrozole increases lev-
els of ERα and restores sensitivity to letrozole. The 
combination of trastuzumab and letrozole pro-
vided higher anticancer effects compared with 
trastuzumab or letrozole alone. In another model, 
lapatinib in combination with tamoxifen effectively 
inhibited the growth of tamoxifen-resistant HER2 
overexpressing Michigan Cancer Foundation-7 
(MCF-7) mammary tumor xenografts [Chu et al. 
2005]. Xia and colleagues confirmed that acquired 
resistance to lapatinib is mediated by a switch in 
cell survival dependence [Xia et  al. 2006]. This 
regulation from HER2 results in codependence 
on ER and HER2. Increased ER signaling in 
response to treatment by lapatinib is enhanced by 
the activation of factors facilitating the transcrip-
tional activity of ER. These findings provided 
the rationale for preventing the development of 
acquired resistance to lapatinib by simultaneously 
inhibiting both ER and HER2 signaling pathways. 
In their model, Giuliano and colleagues reported 
that neoadjuvant treatment with lapatinib leads to 
a rapid increase in ER expression in HER2 BC and 
demonstrated that cotargeting ER along with 
HER2-targeted therapies circumvents this type of 
resistance. They also found that endocrine therapy 
delays tumor progression in the presence of 
restored ER expression in xenograft tumors treated 
with anti-HER2 therapy [Giuliano et  al. 2015]. 
These preclinical models are a proof of concept 
that dual targeting of ER and HER2 is of consider-
able clinical interest.
Clinical evidence: results of phase II/III 
trials
We would like to emphasize the importance of 
this ‘new entity’ of ‘triple-positive breast cancer’ 
by analyzing, if mentioned, results of this sub-
group in phase III and some important phase II 
trials in the field of HER2-positive BC. Different 
outcomes based on ER status is the basis for the 
design of new clinical trials evaluating specific 
treatment approaches for ER-positive, HER2-
positive BC.
Neoadjuvant phase II/III trials
The pathological complete remission (pCR) rate 
is lower in ER-positive, HER2-positive BC versus 
ER-negative HER2-positive BC in neoadjuvant 
settings (Table 1). The difference in pCR rates 
between ER-positive and ER-negative cancers 
varies between trials according to the type of 
chemotherapy and the HER2-directed agent 
under study. The pCR rate has a clear prognostic 
value in HER2-positive ER-negative BC [Nahta 
and O’Regan, 2012], but this relationship 
between pCR and outcome in HER2-positive 
ER-positive BC has not been demonstrated.
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Indeed, in a recent meta-analysis including more 
than 6000 patients, von Minckwitz and colleagues 
showed that pCR is not prognostic in HER2-
positive ER-positive BC [von Minckwitz et  al. 
2012]. Furthermore, a pooled analysis of 12 
international trials including a total of 11,955 
patients does not allow validation of pCR as a 
surrogate endpoint for improved event-free sur-
vival and overall survival in BC [Cortazar et  al. 
2014]. Although long-term follow up of these 
neoadjuvant trials is not yet available, it seems 
that pCR has no prognostic value. Bhargava and 
colleagues divided HER2-positive BC into three 
subgroups based on the level of expression of ER 
and PgR [Bhargava et al. 2011]. They reported an 
inverse correlation between the pCR rate and the 
level of ER expression. These data suggest that 
treatment options other than chemotherapy 
should be evaluated for these HER2-positive BC 
cases and high levels of ER expression. This 
option could associate anti-HER2-targeted thera-
pies and endocrine therapy. This strategy was 
evaluated in the phase II neoadjuvant trial 
TBCRC006 [Rimawi et al. 2013]. The aim of the 
study was to show that an optimal blockade of the 
HER pathway and its potential escape mecha-
nisms (activation of the ER pathway) without 
chemotherapy may induce pCR in many patients. 
Although inhibition of ER using letrozole with or 
without goserelin in combination with trastu-
zumab and lapatinib resulted in tumor responses, 
the pCR rate was unfortunately low [Nahta and 
O’Regan, 2012].
It is interesting to note that in NeoALLTO 
[Baselga et al. 2012a] and NeoSPHERE [Gianni 
et  al. 2012], dual anti-HER2 therapy compared 
with single-agent anti-HER2 treatments was 
associated with higher pCR rates independent of 
the receptor status. These findings support the 
hypothesis that complete blockade of the HER 
receptor family in HER2-positive BC, along with 
targeting of ER simultaneously when coexpressed, 
may be necessary for optimal therapy.
All current data in the neoadjuvant setting suggest 
the existence of a subset of ER-positive, HER2-
positive BC that behaves more like an ER-positive, 
HER2-negative BC. Low pCR rates after neoad-
juvant chemotherapy with or without HER2-
directed agents are observed in these patients; 
pCR is not predictive of outcome in this subtype 
of BC. High levels of ER expression are observed 
in these patients. These patients might need sys-
temic treatments associating anti-HER2-targeted 
therapies and hormonal therapy; thus, chemother-
apy can be avoided [Nahta and O’Regan, 2012]. 
Continued follow up of the reported neoadjuvant 
trials is important to monitor patients for late 
recurrences similar to what is seen in ER-positive, 
HER2-negative BC. The role of extended adju-
vant endocrine therapy in ER-positive, HER2-
positive cancers must be evaluated further.
Phase III trials in the adjuvant setting
As summarized in Table 2, a similar benefit in 
terms of relative improvement in DFS is obtained 
by adding trastuzumab to standard systemic ther-
apy in ER-positive and ER-negative subgroups. 
However, patients presenting an ER-positive BC 
have a longer DFS in these studies. This agrees 
with previous observations indicating that a sub-
set of ER-positive and HER2-positive BC cases 
behave similar to ER-positive and HER2-negative 
BC in terms of late relapse risk.
It is very interesting to note that only one trial, the 
TEACH trial that evaluated the addition of lapat-
inib to standard therapy after the end of chemo-
therapy, showed a significant difference in relative 
improvements in DFS in ER-positive and 
ER-negative patients. Lapatinib was sometimes 
administered very late during long-term follow up.
One of the possible explanations for poorer per-
formance in ER-positive tumors is that 19% of 
these patients did not receive endocrine therapy 
concomitantly with lapatinib in the TEACH trial 
[Goss et al. 2013]. In other trials, endocrine ther-
apy was administered in every patient with 
ER-positive tumors. This fact might have dimin-
ished the efficacy of lapatinib in this group by 
considering the bidirectional molecular crosstalk. 
These data, if confirmed, suggest that endocrine 
therapy should be evaluated earlier in the course 
of adjuvant therapy for patients with ER-positive, 
HER2-positive early-stage BC relative to current 
recommendations [Nahta and O’Regan, 2012].
Phase III trials in the advanced/metastatic 
setting
Important studies describing the outcome accord-
ing to ER status are summarized in Table 3. The 
EGF104900 trial in patients with heavily pre-
treated HER2-positive metastatic BC demon-
strates the benefit of dual targeting by trastuzumab 
and lapatinib only in patients who are ER nega-
tive. These data support the hypothesis that ER 
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signaling constitutes one of the mechanisms of 
resistance in anti-HER2 targeted therapy. In other 
words, the absence of ER expression could 
enhance HER signaling dependence. This explains 
the difference in the efficacy of dual targeting 
between these two subgroups [Blackwell et  al 
2010, 2012]. In the BOLERO-1 trial, despite the 
fact that this trial did not meet its primary end-
point, a relevant prolongation of PFS is seen in 
ER-negative BC if everolimus is added to taxane- 
and trastuzumab-based therapy for advanced dis-
ease. The effect of everolimus seems to differ 
depending on the expression of ER in HER2-
positive advanced BC if the patients do not receive 
endocrine therapy. Again, the bidirectional cross-
talk could explain that ER signaling is an escape 
mechanism for HER2-targeted therapy independ-
ent of the fact that this therapy produces a more 
complete blockade of HER2 signaling. Inhibition 
of HER2 alone increases signaling through ER. 
Thus, we suppose that the efficacy of the combi-
nation therapy with everolimus and trastuzumab 
might be enhanced with the inhibition of ER sign-
aling in HER2- and ER-positive BC.
Different ongoing trials assess the benefits of add-
ing a PI3K/mTOR inhibitor to endocrine therapy 
and HER2-targeted therapy in patients with 
ER-positive, HER2-positive advanced BC 
[Hurvitz et al. 2015]. A similar observation was 
already made in the BOLERO-3 trial [André 
et al. 2014]. In more heavily pretreated patients, 
the addition of everolimus to vinorelbine and 
trastuzumab resulted only in improved outcome 
in the ER-negative subpopulation during a 
hypothesis-generating analysis. The TAnDEM 
trial was the first phase III study to evaluate the 
combination of an endocrine therapy and trastu-
zumab without chemotherapy as a treatment for 
HER2-positive and ER-positive metastatic BC. It 
met its primary endpoint, although outcomes are 
poor in both treatment arms for most patients.
It is interesting to note that approximately 15% of 
patients who received trastuzumab plus anastro-
zole did not experience disease progression for at 
least 2 years, suggesting that the use of HER2-
targeted therapy with an aromatase inhibitor can 
substantially delay chemotherapy in some patients 
[Kaufman et  al. 2009]. The EGF30008 trial 
[Johnston et  al. 2009] included patients not 
selected for HER2 status and compared the com-
bination of lapatinib and letrozole with letrozole 
alone. As previously mentioned for TAnDEM, 
EGF30008 also supports the hypothesis that 
combined inhibition of both pathways (ER and 
HER2) delays the development of resistance and 
prolongs PFS versus treatments targeting only 
ER. As a result, the onset of palliative chemother-
apy is also delayed.
Although there are some differences in the design 
of these two studies, a relevant difference in the 
median PFS between the combination arms of 
the two studies can also be explained by alterna-
tive hypotheses. It might be partially explained by 
the dual inhibition of HER-1 and HER-2 by lapa-
tinib to provide a more complete blockade of the 
HER pathway [Azim and Piccart, 2010]. The 
eLEcTRA trial confirmed the results of the two 
previous studies. Although the results did not 
reach statistical significance, the trends are glob-
ally similar to the results seen in TAnDEM and 
EGF30008.
This lack of statistical significance may be attrib-
utable to the small number of patients [Huober 
et  al. 2012]. The median time to progression 
observed in these three studies in ER-positive, 
HER2-positive BC treated by endocrine therapy 
alone is very short. These results highlight the 
aggressive nature of these cancers and their low 
sensitivity to endocrine therapy alone. Although 
these studies confirm the superiority of the com-
bined approach over the endocrine treatment 
alone, nearly 50% of patients derive no benefit 
from this combination. This is probably due to 
common mechanisms of resistance involving 
downstream signaling pathways [Azim and 
Piccart, 2010]. In light of the above explanation, 
we can speculate on the implication of the PI3K/
AKT/mTOR pathway. However, these studies 
have a small subset of patients with ER-positive 
and HER2-positive BC that benefits from endo-
crine therapy alone. These cancers behave more 
like ER-positive, HER2-negative cancers and are 
mainly driven by ER signaling [Nahta and 
O’Regan, 2012].
In summary, metastatic studies indicate that 
ER-positive, HER2-positive BC is a distinct 
entity versus ER-negative, HER2-positive BC. 
Within this entity, a heterogeneous response to 
therapies can be observed. Some tumors behave 
more like ER-positive, HER2-negative BC. The 
ER signaling pathway mainly drives these. Others 
can benefit from the combination of endocrine 
therapy and anti-HER2 targeted therapy, which 
provides an opportunity to delay the onset of pal-
liative chemotherapy. The last ones are resistant 
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to this treatment combination and are actually 
best treated by chemotherapy and anti-HER2-
targeted therapy. Today, the best results remain 
those obtained with chemotherapy and trastu-
zumab [Prat and Baselga, 2008]. One of the main 
future challenges is to identify these subsets in 
ER-positive, HER2-positive BC to tailor the 
treatment. This would also better explain the 
mechanisms of treatment resistance.
Therapeutic implications
In the adjuvant setting, systemic therapy includes 
anti-HER2 therapy, chemotherapy and endocrine 
therapy if systemic therapy is indicated. The cur-
rent ongoing discussion concerns optimal treat-
ment in advanced disease settings.
The American Society of Clinical Oncology 
Clinical Practice Guidelines about systemic ther-
apy for patients with advanced HER2-positive 
BC offers specific treatment recommendations 
for ER-positive, HER2-negative BC [Giordano 
et  al. 2014]. As the most appropriate first-line 
treatment, the experts strongly recommend an 
association of HER2-targeted therapy with chem-
otherapy. The association of endocrine therapy 
plus trastuzumab or lapatinib may be an option in 
selected cases. This is a moderately strong recom-
mendation. An endocrine therapy alone may also 
be considered in selected cases with a weak 
strength of recommendation. Unfortunately, 
there are no direct comparisons between endo-
crine therapy combined with HER2-trageted 
therapy and chemotherapy combined with 
HER2-targeted therapy. The studies evaluating 
chemotherapy and HER2-targeted therapy have 
the best results and are the only ones with an 
overall survival benefit. Because some patients 
can benefit from the association of endocrine 
therapy and HER2-targeted therapy and because 
this treatment is much less toxic than chemother-
apy, this combination therapy may be considered 
as an option. For endocrine therapy alone, there 
are insufficient data, but experts think that 
patients who have low-volume disease, long dis-
ease-free interval, indolent disease, significant 
comorbidities (heart failure), a preference to 
avoid intravenous chemotherapy or additional 
toxicity are the most appropriate candidates for 
this treatment.
The National Comprehensive Cancer Network 
guidelines contain less specific recommendations 
for this subgroup [Gradishar et  al. 2016]. The 
experts recommend pertuzumab plus trastu-
zumab in combination with a taxane as a pre-
ferred option for the first-line treatment of 
patients with HER2-positive metastatic BC. The 
combination of trastuzumab and endocrine ther-
apy is another option to be considered for patients 
with HER2-positive metastatic BC who are ER 
positive, but this is not the preferred regimen 
according to these guidelines.
The European School of Oncology–European 
Society for Medical Oncology second interna-
tional consensus guidelines for advanced breast 
cancer (ABC2) state that for patients with 
ER-positive, HER2-positive metastatic breast 
cancer for whom endocrine therapy was chosen, 
anti-HER2 therapy plus endocrine therapy should 
be considered with the initiation of endocrine 
therapy since anti-HER2 therapy in combination 
with endocrine therapy has shown substantial PFS 
benefit compared with endocrine therapy alone 
[Cardoso et al. 2014]. The authors clarified that 
the addition of anti-HER2 therapy in this setting 
has not led to a survival benefit. Ninety percent of 
the experts support this recommendation.
New perspectives
Preclinical and clinical data indicate that 
ER-positive, HER2-positive BC is a subset of BC 
that needs specific treatment approaches consid-
ering the bidirectional crosstalk between the ER 
and the HER2 pathways. Standard endocrine 
monotherapy improves outcomes if added to 
anti-HER2 agents, but it does not allow long-
term disease control. Dual HER2 blockade com-
pared with single blockade by trastuzumab 
improves outcome when added to docetaxel in 
ER-positive and ER-negative HER2-positive BC 
[Swain et  al. 2015]. Although BOLERO 1 and 
BOLERO 3 [Hurvitz et  al. 2015; André et  al. 
2014] failed to define a new standard therapy by 
adding everolimus, evaluating other drugs target-
ing the PI3K/AKT/mTOR pathway remains of 
considerable interest in HER2-positive BC as 
hyperactivation of this pathway is one of the 
mechanisms of resistance to trastuzumab-based 
therapy. Data available in the neoadjuvant setting 
indicate that the pCR rate after standard anti-
HER2-based therapy is lower in tumors present-
ing PI3K mutations [Loibl et al. 2014; Majewski 
et al 2015].
Optimization of the ER pathway blockade seems 
mandatory to further improve disease control in 
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the ER-positive, HER2-positive subgroup. The 
addition of a targeted therapy to endocrine therapy 
versus endocrine therapy alone allows more than a 
doubling in the median PFS in ER-positive, 
HER2-negative BC [Baselga et al. 2012c; Turner 
et  al. 2015]. The next step is to evaluate this 
new strategy in the clinic. We expect that many new 
clinical trials will be designed in the near future to 
test this hypothesis. Some are already recruiting.
For example, Mayer and colleagues are investi-
gating the combination of the α-specific PI3K 
inhibitor BYL719 with letrozole and trastuzumab 
[ClinicalTrials.gov identifier: NCT01791478] 
and Wheler and colleagues are assessing everoli-
mus plus letrozole and trastuzumab 
[ClinicalTrials.gov identifier: NCT02152943] in 
patients with HER2-positive, ER-positive 
advanced BC. Of course, the ultimate goal is not 
only to obtain better disease control in the meta-
static setting but also to identify a subgroup of 
ER-positive, HER2-positive BC in which chemo-
therapy can be deleted in the adjuvant setting. 
The NA-PHER2 trial [ClinicalTrials.gov identi-
fier: NCT02530424] is ongoing and investigates 
the combination of trastuzumab, pertuzumab, 
palbociclib and fulvestrant in the neoadjuvant 
setting. Inhibition of the CDK4/6 complexes rep-
resents a great hope as these complexes act down-
stream of the majority of anti-HER2 and 
endocrine resistance mechanisms. Total ER and 
HER2 pathway blockades may be obtained 
through this ambitious experiment. However, 
there are still many steps before this can become 
a reality. In particular, we do not want to take the 
risk of undertreating patients who can be cured 
today by more aggressive approaches. Strong data 
are needed in the metastatic setting before trials 
can ethically be designed in this field.
Conclusion
ER-positive, HER2-positive BC requires specific 
treatment approaches that consider bidirectional 
crosstalk between the ER and HER2 pathways. 
In the adjuvant setting, high-risk patients have to 
receive anti-HER2 therapy and chemotherapy. 
Deletion of chemotherapy is an important objec-
tive, but in this curative setting we cannot risk 
undertreatment. Consequently, we have to wait 
for additional convincing data in the metastatic 
setting before starting well designed adjuvant tri-
als aiming to develop new standard chemother-
apy-free regimens for this subgroup of BC. In the 
metastatic setting, dual HER2 blockade has 
already demonstrated improved outcomes versus 
standard blockade by trastuzumab alone. The 
addition of drugs acting downstream of the HER2 
receptor, and in particular inhibitors of the PI3K/
AKT/mTOR pathway and inhibitors of the 
CDK4/6 complexes, need further evaluation to 
optimize anti-HER2 therapy while considering 
the mechanism of resistance. Chemotherapy 
remains the standard systemic therapy associated 
with anti-HER2 therapy for most patients. Only 
these therapies have been proven to impact over-
all survival. Endocrine therapy combined with 
anti-HER2 therapy is considered for patients with 
more indolent disease. New directions include 
the association of an agent targeted to endocrine 
therapy and anti-HER2 therapy to overcome 
endocrine therapy resistance. If these approaches 
are more effective than the results observed with 
the same regimens without the targeted agent, 
then chemotherapy may become much less fre-
quently used in advanced settings. The bidirec-
tional crosstalk between the ER and HER2 
pathway is the basis for increasing interest in 
these strategies. We can expect many important 
additional data in this field in the near future 
because many drugs targeting endocrine resist-
ance are currently under development.
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